2025-12-03

Order on the Register of Occupational Diseases Reported from 1 January 2005

The Danish Ministry of Employment issued this Order to establish the updated register of occupational diseases applicable from 1 January 2026, replacing the previous 2024 regulation. It defines the general and specific medical and exposure criteria required for diseases to be recognized as occupational, covering conditions affecting the head, musculoskeletal system, respiratory organs, skin, and cancers. The regulation applies to all decisions regarding disease recognition made on or after the effective date, including reopened cases, and provides a comprehensive index of diseases and hazardous exposures.

Finanstilsynet Denmark logo

Denmark

Finanstilsynet Denmark

Click to view thumbnail

Order on the Register of Occupational Diseases Reported from 1 January 2005

Pursuant to Section 7, Paragraph 1, No. 1, of the Act on Work Injury Insurance, cf. Statutory Order No. 1279 of 4 November 2025, and Section 7, Paragraph 1, No. 1, of the Act on Work Injury Insurance in Greenland, cf. Statutory Order No. 75 of 16 January 2017, and upon the recommendation of the Occupational Disease Committee, the following is enacted:

Section 1. A disease may be recognized as an occupational disease, cf. Section 7, Paragraph 1, No. 1, of the Acts, if the following general conditions are met:

  1. The harmful exposure must have a strength and temporal extent that, according to medical documentation, can cause the disease.
  2. The clinical picture of the disease must, according to medical documentation, correspond to the harmful exposure and the disease.
  3. The disease must not with predominant probability be due to other factors than occupational ones, cf. Section 8, Paragraph 1, of the Act.

Paragraph 2. In addition, special conditions mentioned under the individual points in the register, cf. Annex 1, must be met, see the index in Annex 2 if applicable.

Section 2. This Order enters into force on 1 January 2026.

Paragraph 2. The Order is applied from 1 January 2026 in the determination of whether a disease, reported from 1 January 2005, can be recognized as an occupational disease, including when the case is reopened pursuant to Section 41 of the Act on Work Injury Insurance. For Greenland, the Order applies in the determination of whether a disease, reported from 1 January 2011, can be recognized as an occupational disease, including when the case is reopened pursuant to Section 46 of the Act on Work Injury Insurance in Greenland.

Paragraph 3. This Order also applies to decisions made before the entry into force of the Order and brought before the Appeals Authority. This does not apply, however, if the Order tightens the previous conditions for recognition.

Paragraph 4. Statutory Order No. 1324 of 29 November 2024 on the Register of Occupational Diseases Reported from 1 January 2005 is repealed.

Ministry of Employment, 3 December 2025 Kaare Dybvad Bek / Marianne Sørensen

Statutory Gazette A 2025 Published on 4 December 2025 3 December 2025. No. 1483. Ministry of Employment, Danish Working Environment Authority, file no. 2025-52272 BE010345

Annex 1 Register of Occupational Diseases Reported from 1 January 2005

Point | Disease | Exposures Group A - Head A. 1. Noise-induced hearing loss (DLA professionalis) | Strong noise over several years A. 2. Cataract | Radiant energy A. 3.1. Sugar and flour caries, especially on the facial surfaces of teeth | At least 5 years of tooth-loading exposure in the sugar and flour industry within 7 years A. 3.2. Third or fourth-degree tooth wear of several teeth in the permanent dentition, on the chewing surfaces and/or the cutting edge of front teeth (abrasion) | At least 5 years of tooth-loading production work with abrasive in the air within 7 years Other diseases of the head and brain: Group I, J and K Eye diseases: See also E. 5.2.

Group B: Back, neck-shoulder and hip B. 1. Chronic lower back pain (lumbago/ischialgia, lumbar disc prolapse, degenerative lower back disease) a. Back-loading lifting work with lifting/pulling up of heavy objects and a total daily lifting load of many tons over a longer period b. Back-loading lifting work with commonly occurring, extremely heavy and awkward single lifts and a total daily lifting load of several tons over a longer period c. Back-loading care work with many daily handling of adults or larger disabled children over a longer period d. Back-loading, daily exposure to whole-body vibration from strongly vibrating vehicles over a longer period

B. 2. Chronic neck-shoulder pain (cervicobrachial syndrome) | Rapid repeated movements in shoulders/upper arm, possibly in combination with neck bending and/or static loading of the neck-shoulder girdle, over a longer period B. 3. Osteoarthritis in both hip joints (primary bilateral coxarthrosis) | Hip-loading lifting work with many heavy single lifts and a total daily lifting load of several tons over a long period

Group C: Arm and shoulder C. 1. Tenosynovitis and inflammation-like changes in tendon or tissue around tendon (tendinitis and peritendinitis) | Powerful and repetitive (repeated) work movements, in combination with an assessment of the hand's working position under load C. 2. Carpal tunnel syndrome a. Work with strongly vibrating hand tools for a long time (hand-arm vibrations) b. A combination of rapid repeated, powerful and/or awkward, wrist-loading work movements for a long time c. Work with objects that cause direct and persistent pressure on the median nerve in the carpal tunnel for a long time d. As a complication to tenosynovitis on the flexor side of the wrist, which can be recognized according to the occupational disease register C. 3.1. White fingers (Raynaud's syndrome, Raynaud's disease) | Work with strongly vibrating hand tools (hand-arm vibrations) C. 3.2. Peripheral neuropathy in hand/fingers (Morbus alius nervorum periphericorum) C. 3.3. Osteoarthritis in elbow or wrist (primary arthrosis/other specified forms of arthrosis) C. 3.4. Dupuytren's contracture (Carpal tunnel syndrome: C. 2) C. 4.1. Tennis elbow (lateral epicondylitis) a. Powerful and repetitive (repeated) work movements b. Powerful work movements in awkward positions c. Powerful static work C. 4.2. Golf elbow (medial epicondylitis) C. 5.1. Rotator cuff syndrome/impingement syndrome a. Repetitive (repeated) and powerful shoulder movements, in combination with an assessment of the arm's position under load b. Static lifting of the upper arm to approximately 60 degrees or more C. 5.2. Symptoms from or changes in the long biceps tendon (biceps tendinitis, tendinitis caput longum musculus bicipitis brachii) Other diseases of the arm: Group I

Group D: Leg D. 1. Osteoarthritis in knee joint (gonarthrosis) | Kneeling and/or crouching work for many years D. 2. Inflammation-like changes in a bursa in the knee (bursitis) (Bursitis elsewhere: J. 1.) | Persistent, external pressure for days or over a longer period D. 3. Meniscus disease in the knee joint (lesio meniscus genus) | Work in a crouching position under cramped conditions for days or over a longer period D. 4. Jumper's knee (tendinitis/tendinosis patellaris) | Jumping/running with frequent starts and stops (acceleration/deceleration) during bending and straightening of the knee

Group E: Lungs and airways E. 1. Silicosis | Silica anhydride (contains among other things quartz) (for example during sandblasting, iron casting and stone cutting) E. 2. Pulmonary fibrosis | Other silicon compounds E. 3.1. Pulmonary asbestosis | Asbestos (for example during work with asbestos insulation materials, asbestos-cement (Eternit), brake linings) E. 3.2. Extensive connective tissue formation in the pleura with impaired lung function E. 3.3. Pleural plaques after known asbestos exposure E. 4. Other pneumoconioses, not covered by points E. 1. and E. 3.1. | Dust or vapors from aluminum or its compounds or dust from hard metals E. 5.1. Allergic inflammation of the nasal mucosa (allergic rhinitis) | Dust or vapors from: a. Plants or plant products b. Animals or animal products c. Enzymes, dyes, persulfate salts, synthetic resins or medicines and precursors to these d. Isocyanates and certain anhydrides in epoxy resins E. 5.2. Allergic, inflammation-like changes in the eye's mucous membranes (allergic conjunctivitis) E. 6. Lung disease after organic material (allergic alveolitis, humidifier disease and byssinosis: "farmer's lung", "mushroom worker's lung" and "bird breeder's lung") | Organic materials (for example fungal spores, animal protein etc.) E. 7. Chronic bronchitis/COPD | Vapors/gases/dust and/or smoke for many years E. 8. Asthma (allergic and non-allergic) | Dust or vapors from: a. Plants or plant products b. Animals or animal products c. Chemicals and enzymes: dyes, persulfate salts, synthetic resins, medicines and precursors to these, pesticides, acrylates, chloramine, chloramine-T, quaternary ammonium compounds, formaldehyde, glutaraldehyde, isocyanates, certain anhydrides, epoxy resins and enzymes d. Metals: chromium and certain of its compounds, cobalt, aluminum, nickel, hard metal, platinum salts E. 9. Lung disease with impaired lung function of obstructive type | Isocyanates E. 10. Pneumonia | Vanadium and its compounds Other diseases of lungs, airways and organs: Group I, J and K

Group F: Mental illness F. 1. Post-traumatic stress reaction (when symptoms of the disease arise no later than within 6 months, and the disease is fully present within a few years) | Traumatic events or situations of shorter or longer duration of an exceptionally threatening or catastrophic nature F. 2. Depression with onset in close temporal connection with the stress | War participation that has involved either traumatic events and/or situations of shorter or longer duration of an exceptionally threatening or catastrophic nature

Group G: Skin G. 1. Allergic eczema (Eczema after chromium: I. 5.1, Nickel eczema: I. 9) | Allergens (for example preservatives, rubber additives, latex, food etc.) G. 2. Other irritative skin diseases (for example toxic eczema) | One or more irritants or physical factors Other skin diseases: Group I and K

Group H: Infectious and parasitic diseases H. 1. Infectious and parasitic diseases from animals or animal material (for example tetanus, ornithosis, Q-fever, calf birth fever, anthrax, Weil's disease, tuberculous infection from animals) | Animals, animal material or other relevant source of infection (for example during work in waste treatment plants and pipe networks thereto) H. 2. Infectious diseases from humans (for example hepatitis, staphylococci, tuberculosis, AIDS) | Blood, tissue, tissue fluids or other biological material from persons with the same type of infection H. 3. Tropical diseases (for example malaria, amoebiasis, trypanosomiasis, dengue fever, sandfly fever, Malta fever, relapsing fever, yellow fever, plague, leishmaniasis, framboesia, leprosy, typhus and other febrile diseases caused by rickettsia) | Transmission of disease (infection)

Group I: Diseases after chemical substances I. 1.1. Neuritis | Arsenic and certain of its compounds (for example in chemical and metallurgical industry, in pharmaceutical industry and in production of acids and wood impregnation agents) I. 1.2. Cirrhosis of the liver I. 2. Berylliosis | Beryllium and certain of its compounds (for example in porcelain and ceramic industry and electronic and nuclear (atom) industry) Carbon monoxide, phosgene, hydrocyanic acid, cyanide, cyan compounds and cyanates (I. 3): I. 3.1. Toxic brain damage/dementia (severe carbon monoxide poisoning with unconsciousness, toxic encephalopathy) | Carbon monoxide I. 3.2. Hepatitis (hepatitis toxica) | Acrylonitril I. 4. Kidney damage (cadmium poisoning) | Cadmium and certain of its compounds (for example in galvanizing and paint industry) I. 5.1. Allergic eczema | Chromium and certain of its compounds (for example in metal and paint industry, during cement casting and use of chrome-tanned products) I. 5.2. Inflammation of mucous membranes in eyes and upper airways I. 5.3. Perforation of nasal septum I. 6.1. Toxic brain damage/dementia (toxic encephalopathy) | Mercury and certain of its compounds (for example in electrochemical and electromechanical industry, in laboratory work and in production of measuring instruments) I. 6.2. Kidney damage (nephrotic syndrome) I. 7. Manganism (manganese-induced parkinsonism) | Manganese and certain of its compounds after severe exposure (for example in production of dry cells as well as paints and varnishes) I. 8. Lung damage a. Nitric acid, nitrogen oxides or ammonia and its compounds after severe exposure (for example in production of artificial fertilizer, explosives, paints and varnishes, in metal etching, lime burning, nitric acid use, combustion of nitrogen-containing products (artificial fertilizer) and in refrigeration plants) b. Sulfur dioxide or sulfuric acid after severe exposure (for example in production of sulfuric acid and in paper, accumulator, soap and artificial silk industry) c. Chlorine, bromine and iodine and their inorganic compounds, as well as fluorine and its compounds, after severe exposure (for example as bleaching agents in industry) I. 9. Allergic eczema | Nickel I. 10. Hard metal lung | Cobalt (for example in production of special steel, coins and jewelry) I. 11.1. Polyneuropathy | Phosphorus and certain of its compounds I. 11.2. Pulmonary edema with lung damage (for example in production of pesticides) I. 12.1. Toxic brain damage/dementia (toxic encephalopathy) | Lead (for example in accumulator, paint and plastic industry) I. 12.2. Neuritis (peripheral polyneuropathy) I. 12.3. Kidney damage (chronic interstitial nephritis) I. 13. Toxic brain damage/dementia (toxic encephalopathy) | Hydrogen sulfide after severe exposure I. 14. Thallium poisoning (hair loss, neuritis and visual disturbances) | Thallium and its compounds (for example in production of fireworks and rat poison) I. 15. Fluorosis (bone disease) | Fluorine and its compounds after severe exposure Hydrocarbons and their derivatives (I. 16): (for example chemical products with content of organic solvents (paints, varnishes, cleaning agents, raw materials from the chemical industry and plastic industry etc.) I. 16.1. Toxic brain damage/dementia (toxic encephalopathy) | Organic solvents I. 16.2. Kidney damage (glomerulonephritis) I. 16.3. Hepatitis (hepatitis toxica) | Chlorinated solvents I. 16.4. Anemia (aplastic anemia) | Benzene I. 16.5. Neuritis (peripheral polyneuropathy) | Hexane and methyl butyl ketone I. 17. Hepatitis (hepatitis toxica) | Dimethylformamide (for example chemical products with content of amines, nitramines etc., within food, dye and explosive industry etc.) Other diseases after chemical substances: Group E, G and K

Group J: Other diseases J. 1. Inflammation-like changes in a bursa, other places than knee (bursitis) (Bursitis in knee: D. 2) | Persistent, external pressure for days or over a longer period J. 2. Nerve paralysis | External pressure J. 3. Diseases as a result of work in compressed air | Work in compressed air

Group K: Cancer diseases1) Blood- and lymph-forming organs: K. 1.1. Leukemia | Substances: a. Benzene b. Ethylene oxide c. 1,3-Butadiene Processes: d. Styrene and styrene-7,8-oxide e. Rubber industry f. Oil refining g. Boot and shoe manufacturing and repair K. 1.2. Myeloid leukemia a. Ionizing radiation (for example X-ray and gamma radiation) b. Formaldehyde c. Styrene and styrene-7,8-oxide K. 1.3. Lymph- and blood-forming organs a. 1,3-Butadiene b. Styrene and styrene-7,8-oxide c. Rubber industry K. 1.4. Non-Hodgkin lymphoma a. 2,3,7,8-Tetrachlorodibenzo-para-dioxin (dioxin) b. Trichloroethylene c. Styrene and styrene-7,8-oxide d. Rubber industry Digestive organs: K. 2.1. Peritoneum (mesothelioma) a. Asbestos b. Erionite c. Talcum with content of asbestos-like fibers K. 2.2. Liver and bile ducts a. Aflatoxins b. Trichloroethylene K. 2.3. Liver a. Hepatitis B virus b. Hepatitis C virus c. Vinyl chloride K. 2.4. Liver (angiosarcoma) | Vinyl chloride K. 2.5. Stomach a. Inorganic lead compounds b. Rubber industry K. 2.6. Nasopharynx | Formaldehyde Skin: K. 3. Skin, including also precursor to skin cancer (actinic keratosis) Substances: a. Arsenic and its compounds b. Anthracene c. Creosote compounds d. Mineral oil, untreated and lightly treated e. Raw paraffin f. Shale oil or lubricants extracted from shale g. Solar radiation h. Carbon black i. Coal tar and coal tar pitch Processes: j. Coke production k. Coal gasification l. Oil refining Airways: K. 4.1. Lung | Substances: a. 2,3,7,8-Tetrachlorodibenzo-para-dioxin (dioxin) b. Alpha-chlorinated toluenes and benzoyl chloride (combined) c. Arsenic and its compounds d. Asbestos e. Beryllium and its compounds f. Bis(chloromethyl)methyl ether and chloromethyl ether (technical grade) (oat cell) g. Cadmium and its compounds h. Insecticides (non-arsenic-containing) i. Chromium compounds j. Crystalline quartz k. Nickel compounds, including combinations of nickel oxides and sulfides in nickel refining industry l. Particles of metallic cobalt with content of tungsten carbide (tungsten) m. Passive smoking n. Radon and "radon daughters" o. Mustard gas (sulfur mustard) p. Carbon black q. Coal tar and coal tar pitch r. Strong inorganic acid mists containing sulfuric acid s. Talcum with content of asbestos-like fibers t. Exhaust gases from diesel engines u. Bitumen during asphalt roof work Processes: v. Welding fumes arising from welding in metal w. Aluminum production x. Iron and metal casting y. Coke production z. Coal gasification æ. Painter (occupational exposure as) ø. Mining of iron ore (iron glances) with radon exposure å. Production of artificial glass, glass containers and pottery aa. Rubber industry K. 4.2. Pleura (mesothelioma) a. Asbestos b. Erionite c. Talcum with content of asbestos-like fibers K. 4.3. Nasal cavity and sinuses | Substances: a. Formaldehyde b. Chromium compounds c. Nickel compounds, including combinations of nickel oxides and sulfides in nickel refining industry d. Wood dust Processes: e. Production of isopropyl alcohol by strong acid process f. Furniture and cabinet production g. Boot and shoe manufacturing and repair K. 4.4. Mucous membranes in sinuses and mastoid process (epithelial tumors) | Radium-226 K. 4.5. Larynx | Substances: a. Asbestos b. Mustard gas (sulfur mustard) c. Strong inorganic acid mists containing sulfuric acid Processes: d. Isopropyl alcohol, production by strong acid process Urinary tract: K. 5.1. Kidney | Substances: a. Trichloroethylene b. PFOA (perfluorooctanoic acid) Processes: c. Coke production K. 5.2. Urinary bladder | Substances: a. 2-Naphthylamine b. 4-Aminobiphenyl c. 4-Chloro-o-toluidine and its strong (hydrochloride) salts d. 4,4'-Methylenebischloroaniline (MOCA) e. Arsenic and its compounds f. Benzidine and benzidine-based dyes g. Ortho-toluidine h. Coal tar and coal tar pitch i. Tetrachloroethylene j. Carbon black, PAH (polycyclic aromatic hydrocarbons) and exhaust gases from diesel engines Processes: k. Aluminum production l. Auramine production m. Hairdressing n. Coal gasification o. Rubber industry p. Painter (occupational exposure as) q. Magenta production (fuchsin) r. Boot and shoe manufacturing and repair Other organs or cancer forms: K. 6.1. Connective tissue | 2,3,7,8-Tetrachlorodibenzo-para-dioxin (dioxin) K. 6.2. Breast | Ionizing radiation (for example X-ray and gamma radiation) K. 6.3. Bone (sarcoma) | Radium-226 and Radium-228 K. 6.4. Cancer without specification (all cancer forms, which are not included under other points) | 2,3,7,8-Tetrachlorodibenzo-para-dioxin (dioxin) K. 6.5. Thyroid gland | Ionizing radiation (for example X-ray and gamma radiation) K. 6.6. Skin cancer (malignant melanoma) in the eye | UV radiation in connection with welding in metals K. 6.7. Testicular cancer | PFOA (Perfluorooctanoic acid)

Group L: Fetal damage Fetal disease/damage | Documented infection/exposure in the mother during pregnancy Consequences of infections: L. 1.1. Congenital cytomegalovirus infection | Cytomegalovirus L. 1.2. Neonatal hepatitis B virus infection leading to chronic carrier state | Hepatitis B virus L. 1.3. Neonatal herpes | Herpes simplex virus L. 1.4. Congenital or neonatal HIV infection | Human immunodeficiency virus (HIV) L. 1.5. Encephalitis | Listeria L. 1.6. Congenital infection | Parvovirus B-19 L. 1.7. Congenital rubella syndrome | Congenital rubella syndrome (rubella virus) L. 1.8. Microcephaly, hydrocephalus, retinitis, hepatitis | Toxoplasmosis (toxoplasmosis) L. 1.9. Congenital varicella syndrome or neonatal varicella | Varicella zoster virus (chickenpox virus) Consequences of chemical substances: L. 2.1. Microcephaly, mental retardation | Methylmercury L. 2.2. Encephalitis, retarded development | Lead Consequences of other harmful exposures: L. 3.1. Microcephaly, malignant diseases | Radiation (radioactivity) L. 3.2. Premature birth and complications thereto | Extreme physical work load Consequences of physical trauma: L. 4. Premature birth and complications thereto | Accidents and violence

  1. The content in group K is based on IARC's monograph series (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans), volumes 1-88, volume 100F, volume 103 and volume 106. WHO International Agency for Research on Cancer, Lyon.

Annex 2 Index

The index contains diseases, exposures and concepts mentioned in Annex 1, cf. Section 1 of the Order. Although the disease and/or exposure is mentioned in the register, it does not necessarily mean that the disease and/or exposure is covered by the same register. Attention is drawn to the fact that both the general conditions, as they appear in Section 1 of the register, and the special conditions mentioned in the individual points must be met, cf. Section 1, Paragraph 2.

Disease/exposure/concept: Group/point: 1,3-Butadiene | K. 1.1.c, K. 1.3 2-Naphthylamine | K. 5.2.a 2,3,7,8-Tetrachlorodibenzo-para-dioxin (dioxin) | K. 1.4.a, K. 4.1.a, K. 6.1, K. 6.4 4-Aminobiphenyl | K. 5.2.b 4-Chloro-o-toluidine and its strong (hydrochloride) salts | K. 5.2.c 4,4'-Methylenebischloroaniline (MOCA) | K. 5.2.d A: Abrasion (tooth wear) | A. 3.2 Acceleration/deceleration (starts/stops) | D. 4 Acrylonitrile | I. 3.2. Aflatoxins | K. 2.2.a AIDS/HIV | H. 2, L. 1.4 Accumulator industry | I. 12, I. 13 Actinic keratosis (precursor to skin cancer) | K. 3 Elbow (tennis elbow and golf elbow) | C. 4.1, C. 4.2 Alpha-chlorinated toluenes and benzoyl chloride (combined) | K. 4.1.b Allergic inflammation of nasal mucous membranes (allergic rhinitis) | E. 5.1 Allergic inflammation-like changes in the eye's mucous membranes (allergic conjunctivitis) | E. 5.2 Allergic eczema | G. 1, I. 5.1, I. 9. Allergic alveolitis | E. 6 Allergic asthma | E. 8 Aluminum | E. 4, E. 8, K. 4.1.v, K. 5.2.k Aluminum production | E. 4, E. 8, K. 4.1.v, K. 5.2.k Aminobiphenyl | K. 5.2.b Amines, nitramines | I. 17 Ammonia | I. 8. A Amoebiasis | H. 3 Angiosarcoma (primary liver cancer) | K. 2.4 Anhydrides | E. 5, E. 8 Anthracene | K. 3.b Aplastic anemia | I. 16.4 Arsenic | I. 1.1, I. 1.2, K. 3.1.a, K. 4.1.c, K. 5.2.e Primary bilateral coxarthrosis (osteoarthritis in both hip joints) | B. 3 3 December 2025. 17 No. 1483.

Arthrosis, genus (osteoarthritis in knee) | D. 1 Asbestos, asbestos diseases | E. 3.1., E. 3.2, E. 3.3, K. 2.1.a, K. 4.1.d, K. 4.2.a, K. 4.5.a Asbestos-like fibers, talcum with | K. 2.1.c, K. 4.2.c Asbestosis | E. 3.1 Asphalt roof work (bitumen) | K. 4.1.u Asthma, bronchial asthma | E. 8 Atom (nuclear) industry | I. 2 Auramine production | K. 5.2.l B: Pitch (coal tar pitch) | K. 3.1.i, K. 4.1.q, K. 5.2.h Benzene | I. 16.4, K. 1.1.a Benzo[a]pyrene | K. 3, K. 4.1, K. 5.1, K. 5.2 Benzidine and benzidine-based dyes | K. 5.2.f Benzoyl chloride | K. 4.1.b Beryllium, berylliosis | I. 2, K. 4.1.e Inflammation of mucous membranes in eyes and upper airways | I. 5.3 Inflammation-like changes in a bursa (bursitis) | D. 2, J. 1 Biceps tendon, changes in (biceps tendinitis) | C. 5.2 Sinus cancer | K. 4.3, K. 4.4 Connective tissue cancer | K. 6.1 »Bird breeder's" | [Text cuts off]

Share